Differential suppression of tumor-specific CD8+ T cells by regulatory T cells

Journal of Immunology

Volumn 185, Issue 9, 2010, Pages 5048-5055

  James, Edward ^a   Yeh, Alex ^a,d   King, Cathy ^a   Korangy, Firouzeh ^b   Bailey, Ian ^a   Boulanger, Denise S ^a   Van Den Eynde, Benoît J ^c   Murray, Nicholas ^a   Elliott, Tim J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOLOGY; CD8+ T LYMPHOCYTE; CELL ISOLATION; COLORECTAL CARCINOMA; CROSS PROTECTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; BAGG ALBINO MOUSE; CROSS REACTION; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CROSS REACTIONS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, REGULATORY;

EID: 78149482693     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000134     Document Type: Article

References (43)

1. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-360.
2. Clemente, C. G., M. C. Mihm, Jr., R. Bufalino, S. Zurrida, P. Collini, and N. Cascinelli. 1996. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310.
3. Zhang, L., J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. N. Liebman, et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:203-213.
4. Pagès, F., A. Berger, M. Camus, F. Sanchez-Cabo, A. Costes, R. Molidor, B. Mlecnik, A. Kirilovsky, M. Nilsson, D. Damotte, et al. 2005. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353:2654-2666.
5. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942-949.
6. Salama, P., M. Phillips, F. Grieu, M. Morris, N. Zeps, D. Joseph, C. Platell, and B. Iacopetta. 2009. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27:186-192.
7. Petersen, R. P., M. J. Campa, J. Sperlazza, D. Conlon, M. B. Joshi, D. H. Harpole, Jr., and E. F. Patz, Jr. 2006. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107:2866-2872.
8. Ghebeh, H., E. Barhoush, A. Tulbah, N. Elkum, T. Al-Tweigeri, and S. Dermime. 2008. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 8:57-68.
9. Miracco, C., V. Mourmouras, M. Biagioli, P. Rubegni, S. Mannucci, I. Monciatti, E. Cosci, P. Tosi, and P. Luzi. 2007. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol. Rep. 18:1115-1122.
10. Bonertz, A., J. Weitz, D. H. Pietsch, N. N. Rahbari, C. Schlude, Y. Ge, S. Juenger, I. Vlodavsky, K. Khazaie, D. Jaeger, et al. 2009. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 119:3311-3321.
11. Shimizu, J., S. Yamazaki, and S. Sakaguchi. 1999. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211-5218.
12. Golgher, D., E. Jones, F. Powrie, T. Elliott, and A. Gallimore. 2002. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32:3267-3275.
13. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59:3128-3133.
14. Sutmuller, R. P., L. M. van Duivenvoorde, A. van Elsas, T. N. Schumacher, M. E. Wildenberg, J. P. Allison, R. E. Toes, R. Offringa, and C. J. Melief. 2001. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25 (+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823-832.
15. Huang, A. Y. C., P. H. Gulden, A. S. Woods, M. C. Thomas, C. D. Tong, W. Wang, V. H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 93:9730-9735.
16. Qin, S., S. Cobbold, H. Tighe, R. Benjamin, and H. Waldmann. 1987. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur. J. Immunol. 17:1159-1165.
17. Lowenthal, J. W., P. Corthésy, C. Tougne, R. Lees, H. R. MacDonald, and M. Nabholz. 1985. High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J. Immunol. 135:3988-3994.
18. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc. Natl. Acad. Sci. USA 90:3539-3543.
19. Tutt, A. L., R. R. French, T. M. Illidge, J. Honeychurch, H. M. McBride, C. A. Penfold, D. T. Fearon, R. M. Parkhouse, G. G. Klaus, and M. J. Glennie. 1998. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 161:3176-3185.
20. Mendoza, L. M., P. Paz, A. Zuberi, G. Christianson, D. Roopenian, and N. Shastri. 1997. Minors held by majors: the H13 minor histocompatibility locus defined as a peptide/MHC class I complex. Immunity 7:461-472.
21. Sanderson, S., and N. Shastri. 1994. LacZ inducible, antigen/MHC-specific T cell hybrids. Int. Immunol. 6:369-376.
22. Kanaseki, T., and N. Shastri. 2008. Endoplasmic reticulum aminopeptidase associated with antigen processing regulates quality of processed peptides presented by MHC class I molecules. J. Immunol. 181:6275-6282.
23. Brichard, V., A. Van Pel, T. Wölfel, C. Wölfel, E. De Plaen, B. Lethé, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489-495.
24. Coulie, P. G., V. Brichard, A. Van Pel, T. Wölfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35-42.
25. Udaka, K., T. J. Tsomides, and H. N. Eisen. 1992. A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein. Cell 69:989-998.
26. Holtappels, R., D. Thomas, J. Podlech, G. Geginat, H. P. Steffens, and M. J. Reddehase. 2000. The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells. J. Virol. 74:1871-1884.
27. Hammer, G. E., F. Gonzalez, M. Champsaur, D. Cado, and N. Shastri. 2006. The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat. Immunol. 7:103-112.
28. Rammensee, H., J. Bachmann, N. P. Emmerich, O. A. Bachor, and S. Stevanović. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219.
29. Acosta-Rivero, N., S. Dueñas-Carrera, L. Alvarez-Lajonchere, and J. Morales-Grillo. 2004. HCV core protein-expressing DNA vaccine induces a strong class I-binding peptide DTH response in mice. Biochem. Biophys. Res. Commun. 314:781-786.
30. López, D., Y. Samino, U. H. Koszinowski, and M. Del Val. 2001. HIV envelope protein inhibits MHC class I presentation of a cytomegalovirus protective epitope. J. Immunol. 167:4238-4244.
31. Simeckova-Rosenberg, J., Z. Yun, P. R. Wyde, and M. Z. Atassi. 1995. Protection of mice against lethal viral infection by synthetic peptides corresponding to B-and T-cell recognition sites of influenza A hemagglutinin. Vaccine 13:927-932.
32. Malcolm, T. 2007. Regulatory T cell control of anti-tumour responses. Masters Thesis, University of Southampton
33. Haeryfar, S. M., R. J. DiPaolo, D. C. Tscharke, J. R. Bennink, and J. W. Yewdell. 2005. Regulatory T cells suppress CD8+ T cell responses induced by direct priming and cross-priming and moderate immunodominance disparities. J. Immunol. 174:3344-3351.
34. Yewdell, J. W., and J. R. Bennink. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17:51-88.
35. Casares, N., L. Arribillaga, P. Sarobe, J. Dotor, A. Lopez-Diaz de Cerio, I. Melero, J. Prieto, F. Borrás-Cuesta, and J. J. Lasarte. 2003. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol. 171:5931-5939.
36. Heath, W. R., L. Kjer-Nielsen, and M. W. Hoffmann. 1993. Avidity for antigen can influence the helper dependence of CD8+ T lymphocytes. J. Immunol. 151:5993-6001.
37. Hofmann, M., M. Radsak, G. Rechtsteiner, K. Wiemann, M. Günder, U. Bien-Gräter, R. Offringa, R. E. Toes, H. G. Rammensee, and H. Schild. 2004. T cell avidity determines the level of CTL activation. Eur. J. Immunol. 34:1798-1806.
38. Janas, M. L., P. Groves, N. Kienzle, and A. Kelso. 2005. IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation. J. Immunol. 175:8003-8010.
39. Barthlott, T., H. Moncrieffe, M. Veldhoen, C. J. Atkins, J. Christensen, A. O'Garra, and B. Stockinger. 2005. CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. Int. Immunol. 17:279-288.
40. De La Rosa, M., S. Rutz, H. Dorninger, and A. Scheffold. 2004. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur. J. Immunol. 34:2480-2488.
41. Scheffold, A., J. Hühn, and T. Höfer. 2005. Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-) two to tango. Eur. J. Immunol. 35:1336-1341.
42. DeLeo, A. B., H. Shiku, T. Takahashi, M. John, and L. J. Old. 1977. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J. Exp. Med. 146:720-734.
43. Schiavetti, F., J. Thonnard, D. Colau, T. Boon, and P. G. Coulie. 2002. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res. 62:5510-5516.